



Contacts: Tularik Inc.
Traci McCarty, 650/825-7182 (investors/media)

Tularik to Webcast Conference Call on 2003 Third Quarter Financial Results

South San Francisco, Calif. – (BW HealthWire) – Oct. 7, 2003 – Tularik Inc. (Nasdaq:TLRK) will host a live webcast of its conference call discussing the Company's 2003 third quarter financial results at 1:30 p.m. Pacific Time on Thursday, October 16, 2003. The call will be hosted by David V. Goeddel, Ph.D., Chief Executive Officer. Tularik will issue a press release regarding the 2003 third quarter financial results after the market closes on October 16, 2003.

The press release and the live webcast can be accessed by visiting Tularik's Internet website at www.tularik.com under the "Investors/Media" tab. Following the webcast, an archived version of the call will be available at the same address for five days.

About Tularik

Tularik is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, immunology and metabolic disease. The Company currently has four drug candidates in clinical trials. In the cancer area, Tularik is currently conducting a pivotal study of T67 for the treatment of hepatocellular carcinoma (HCC) and Phase 2 trials with T607 for the treatment of HCC, ovarian cancer, gastric cancer and esophageal cancer. T487, for the treatment of inflammatory diseases, and T131, for the treatment of type 2 diabetes, are in Phase 1 trials to evaluate safety and pharmacokinetic parameters. For more information, visit Tularik's Internet website at www.tularik.com.